Author(s):
Dinesh B. Marathe, Rohini M. Koli, Kunal S. Mahajan, Dr. R. R. Patil, Vinod A. Chaure
Email(s):
vinodchaure1992@gmail.com
DOI:
10.52711/2231-5675.2023.00035 
Address:
Dinesh B. Marathe, Rohini M. Koli, Kunal S. Mahajan, Dr. R. R. Patil, Vinod A. Chaure*
Department of Pharmaceutical Chemistry, J.E.S’s College of Pharmacy, Nandurbar, 425412, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 13,
Issue - 3,
Year - 2023
ABSTRACT:
As an antidepressant, escitalopram oxalate, a pure S-enantiomer derivative of citalopram, blocks selective serotonin reuptake. By preventing serotonin reuptake and boosting serotonin levels in synaptic clefts, this action exerts an antidepressant effect. The analytical method used to identify Escitalopram oxalate in pharmaceutical formulations, both alone and in combination with other antidepressants, was identified in this review. The simultaneous comparison and discussion of eighteen analytical techniques, including HPLC, HPTLC, stability-indicating strategies, UV spectroscopy, hyphenated techniques and bioanalytical procedures, is best demonstrated by this thorough analysis. Analytical development must be validated in order to produce reliable results for regulatory filings. The invention of drugs resulted in a revolution in human health.
Cite this article:
Dinesh B. Marathe, Rohini M. Koli, Kunal S. Mahajan, Dr. R. R. Patil, Vinod A. Chaure. Analytical Review on Escitalopram oxalate and their combinations in Bulk and Pharmaceutical Formulation. Asian Journal of Pharmaceutical Analysis. 2023; 13(3):217-1. doi: 10.52711/2231-5675.2023.00035
Cite(Electronic):
Dinesh B. Marathe, Rohini M. Koli, Kunal S. Mahajan, Dr. R. R. Patil, Vinod A. Chaure. Analytical Review on Escitalopram oxalate and their combinations in Bulk and Pharmaceutical Formulation. Asian Journal of Pharmaceutical Analysis. 2023; 13(3):217-1. doi: 10.52711/2231-5675.2023.00035 Available on: https://ajpaonline.com/AbstractView.aspx?PID=2023-13-3-11
REFERENCES:
1. Sharma S. Rajpurohit H. Sonwal C. Bhandari A. Choudhary V.R. and Jain T. Zero order spectrophotometric method for estimation of escitalopram oxalate in tablet formulations. Journal of Young Pharmacists. 2010; 2(4):420. DOI: 10.4103/0975-1483.71626.
2. Zohar J. Escitalopram in the treatment of obsessive–compulsive disorder. Expert Review of Neurotherapeutics. 2008; 8(3): 339-349. doi.org/10.1586/14737175.8.3.339.
3. Marathe S R. Patil A S. Ganorkar S B. Chaudhari S. and Shirkhedkar A A. A brief review on analytical methods for estimation of isradipine in pharmaceutical formulation and biological matrices. Journal of the Chilean Chemical Society. 2019; 64(3):4565-4570. doi.org/10.4067/S0717-97072019000304565.
4. Chaure V A. Ganorkar S B. Chaturbhuj G U. Surana S J. and Shirkhedkar A A. A Precise Review on TenofovirDisoproxilFumarate: An Analytical Profile. Journal of Pharmaceutical Technology, Research and Management. 2018; 6(2):153-167. DOI: 10.15415/jptrm.2018.62012.
5. Kirino E Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability. Patient Preference and Adherence. 2012; 853-861.doi.org/10.2147/PPA.S22495.
6. Garnock-Jones K P. and McCormack P.L. Escitalopram: a review of its use in the management of major depressive disorder in adults. CNS Drugs. 2010; 24:769-796. doi.org/10.2165/11204760-000000000-00000.
7. Dhillon S. Scott L J. and Plosker G L. Escitalopram: a review of its use in the management of anxiety disorders. CNS Drugs. 2006; 20 :763-790. doi.org/10.2165/00023210-200620090-00010.
8. Indian Pharmacopoeia, 2018, Volume II, published by The Indian Pharmacopoeia Commission, Ghaziabad, Page no: 1975-1978.
9. United States Pharmacopoeia, National Formulary, 2012, Volume 2, 3094-3097.
10. Picollo M. Aceto M. and Vitorino T. UV-Vis spectroscopy. Physical Sciences Reviews. 2018; 4(4):20180008. DOI: 10.1515/psr-2018-0008
11. Passos M L. and Saraiva M M. Detection in UV-visible spectrophotometry: Detectors, detection systems, and detection strategies. Measurement. 2019; 135:896-904. doi.org/10.1016/j.measurement.2018.12.045.
12. Suneetha A. and Sundar B S. A validated UV spectrophotometric method for estimation of Escitalopram Oxalate in bulk and pharmaceutical dosage forms. Asian Journal of Research in Chemistry. 2010; 3(4):935-937.
13. Kakde R B. and Satone D D. Spectrophotometric method for simultaneous estimation of escitalopram oxalate and clonazepam in tablet dosage form. Indian Journal of Pharmaceutical Sciences. 2009; 71(6):702. https://doi.org/10.4103%2F0250-474X.59559.
14. Oxalate, E., Bulk, C.I. and Form, I.T.D., Innovative Drug Discovery.
15. Patel D J. Patel M J. Patel J K. and Patel V. Simultaneous determination of escitalopram oxalate 6 and eszopiclone in their combined mixture by ultraviolet spectrophotometry (Dual 7 wavelength method). Analytical Chemistry an Indian Journal. 2013; 12(10):398-402.
16. Kupiec T. Quality-control analytical methods: High-performance liquid chromatography. International Journal of Pharmaceutical Compounding. 2004; 8:223-227.
17. Malviya R. Bansal V. Pal O P. and Sharma P K. High performance liquid chromatography: a short review. Journal of Global Pharma Technology. 2010; 2(5):22-26.
18. Lasan V M. Analytical method development and method validation for escitalopram oxalate in pharmaceutical dosage form (Doctoral dissertation, Ganpat University).
19. Devi M M. Kalyani K. Sukanya M and Padmalatha H. 2019. Development and Validation of HPLC Method for he Estimation of Escitalopram Oxalate and Tolterodine Tartrate in oral Dosage Forms. DOI: 10.20959/WJPR20193-14380.
20. Mondal P. Santhosh B. Satla S R and Raparla R. A new validated simultaneous RP-HPLC method for estimation of escitalopram oxalate and etizolam in bulk and table dosage form. Der Pharma Chemica. 2013; 5(3):26-32. 10.5958/2231-5675.2019.00032.2
21. Kakde R B. Satone D D. Gadapayale K K. and Kakde M G. Stability-indicating RP-HPLC method for the simultaneous determination of escitalopram oxalate and clonazepam. Journal of Chromatographic Science. 2013; 51(6):490-495. doi.org/10.1093/chromsci/bms177.
22. Bhimanadhuni C N. Garikapati D R. and Usha P. Development and validation of an RP-HPLC method for the simultaneous determination of Escitalopram Oxalate and Clonazepam in bulk and its pharmaceutical formulations. International Current Pharmaceutical Journal. 2012; 1(8) :193-198. doi.org/10.3329/icpj.v1i8.11249.
23. Krishna V. Gouthami B. Meyyanathan S. Gowramma B. Elango K. and Suresh B. In vitro In vivo pharmacokinetic interaction study of escitalopram oxalate when co administered with caffeine/caffeinated beverages. In The Open Conference Proceedings Journal. 2013; (Vol. 4:66-71).
24. Panchale W A. Nimbokar S W. Gudalwar B R. Bakal R L. and Manwar J V. RP-HPLC method for simultaneous determination of escitalopram oxalate and flupentixol HCl in tablet dosage form. GSC Biological and Pharmaceutical Sciences. 2021; 14(1):169-174. DOI: 10.30574/gscbps.2021.14.1.0004.
25. Ramu B. and Chittela K B. High Performance Thin Layer Chromatography and Its Role Pharmaceutical Industry. Open Sci. J. Biosci. Bioeng. 2018; 5(3):29-34.
26. Srivastava M. ed. High-performance thin-layer chromatography (HPTLC). Springer Science & Business Media.
27. Kakde R. Satone D and Bawane N. HPTLC method for simultaneous analysis of escitalopram oxalate and clonazepam in pharmaceutical preparations. JPC–Journal of Planar Chromatography–Modern TLC. 2009; 22:417-420. DOI: 10.1556/JPC.22.2009.6.5.
28. Quadri S. Sonwane L. Poul B. and Kamshette S. Review on stability indicating assay methods (SIAMs). PharmaTutor. 2014; 2(8):16-31.
29. Chaudhari J I G A R. and Chhabra G. Development and validation of stability indicating RP-HPLC method for natamycin in bulk and ophthalmic dosage forms. Asian Journal Pharmaceutical & Clinical Research. 2014; 7(3):54-59.
30. Kakde R B. Satone D D. Gadapayale K K. and Kakde M G. Stability-indicating RP-HPLC method for the simultaneous determination of escitalopram oxalate and clonazepam. Journal of Chromatographic Science. 2013; 51(6):490-495. doi:10.1093/chromsci/bms177.
31. B. Madhu Harika, Y. Rajendra Prasad. A New stability indicating RP-HPLC method for simultaneous estimation of Escitalopram and Lmethylfolate in bulk and tablet dosage form. International Journal of Medical Science and Advanced Clinical Research (IJMACR). 2019; 2(5): 32 – 37.
32. Bhoomaiah B. Jayasree A. and Rambabu D. Stability Indicating RP-HPLC Method for Simultaneous Determination of L-Methyl folate and Escitalopram in Bulk and Pharmaceutical Formulation. Oriental Journal of Chemistry. 2016; 32(6): 3201. DOI: http://dx.doi.org/10.13005/ojc/320643.
33. Vijaya Laxmi, A. Srividya, K. Abbulu. Stability Indicating Method Development and Validation for the Estimation of Escitalopram and L-Methylfolate in Bulk and Pharmaceutical Dosage Form by RP –HPLC. Int. J. of Pharmacy and Analytical Research. 2019; 8(1): 28-37.
34. Kalpana Nekkala, V Shanmukha Kumar J, D Ramachandran, Ganji Ramanaiah and Ganta Srinivas. Method development and validation of stability indicating rp-hplc method for simultaneous estimation of escitalopram oxalate and etizolam in bulk and its pharmaceutical formulations. International Journal of Bioassays. 2014; 3 (11): 3456‐3463.